Prof. Xicai Wang 王熙才
Chief Physician, Professor
Department of Tumor Biological Therapy, Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Biological immunotherapy and chemotherapy for malignant tumors.
Dr. Wang earned a medical degree from Kunming Medical College in 1984 and a master’s in oncology in 1994. Training included research at Peking University Clinical Cancer Institute and advanced study in hematopoietic stem cell transplantation at Beijing 307 Hospital. As a senior visiting scholar at the Chinese University of Hong Kong (2002–2003), Dr. Wang researched gene diagnosis and therapy. Currently Deputy Director of the Tumor Biological Immunotherapy Center at Yunnan Cancer Hospital.
Professional roles
- Director, Anti-tumor Drugs and Tumor Molecular Biology Laboratory
- Council Member, Yunnan Immunology Society
- Council Member, Yunnan Cell Biology Society
- Standing Committee Member, Tumor Marker Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Xicai). Papers usually list the name as Xicai Wang or Wang X.
Selected publications
16 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Biother Radiopharm, 2018 (senior author): The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer. PubMed 30256660
- Mol Med Rep, 2018 (senior author): Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLC‑05 lung cancer cells. PubMed 29115620
- Oncotarget, 2017 (senior author): MicroRNA-370 inhibits the growth and metastasis of lung cancer by down-regulating epidermal growth factor receptor expression. PubMed 29152147
- Tumour Biol, 2016 (senior author): An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth. PubMed 26376999
- Asian Pac J Cancer Prev, 2013 (senior author): Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy. PubMed 23886150
- Int J Biol Markers, 2010 (senior author): Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. PubMed 20586026
- Biol Pharm Bull, 2010 (senior author): Orally administered DNA vaccine delivery by attenuated Salmonella typhimurium targeting fetal liver kinase 1 inhibits murine Lewis lung carcinoma growth and metastasis. PubMed 20118536
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion